Healthcare Industry News: Dako
News Release - May 1, 2009
Fisher HealthCare Becomes Exclusive Distributor of Flow Cytometry Reagents for Dako Reagent Partnership Division
GLOSTRUP, DENMARK--(Healthcare Sales & Marketing Network)--May 1, 2009 -- Dako, Reagent Partnership Division, has entered into a five-year agreement with Fisher HealthCare, a division of Thermo Fisher Scientific. Under this agreement, Fisher Healthcare has been granted the exclusive right to distribute Flow Cytometry reagents in the US acute care market, including hospitals and reference labs.Dako, Reagent Partnership Division, globally supplies Flow Cytometry reagents used for cancer diagnostics in clinical and research laboratories. Dako, Reagent Partnership Division, holds a portfolio of over 240 reagents, which can be used in all conventional flow cytometers.
Fisher HealthCare is a leading distribution channel in the US with a long history of success in the clinical diagnostic market. The partnership between Fisher HealthCare and Dako allows customers to consolidate orders for their central laboratory to include Flow Cytometry reagents and other ancillary supplies.
Christian Kjaer, Vice President, Reagent Partnership Division of Dako, said: "We are delighted to be partnering with Fisher HealthCare to bring outstanding customer service to our customers along with a broad portfolio of world-class product solutions. The agreement furthers Dako's commitment to the growing cancer diagnostics market by strengthening and enlarging the Dako sales channel."
Mark Smits, Vice President, Marketing of Fisher HealthCare, said: "This partnership broadens our cancer-based diagnostic portfolio and allows us to provide a more comprehensive product offering to our customers. We will be better positioned to meet the needs of this market by capitalizing on Dako's long history of quality Flow Cytometry reagents and commitment to the diagnostic market."
About Dako Reagent Partnership Division
Dako is a global leader in tissue-based cancer diagnostics. Hospital and research laboratories worldwide use Dako's knowledge, reagents, instruments and software to make precise diagnoses and determine the most effective treatment for patients suffering from cancer. Employing more than 1000 people and operating in more than 70 countries, Dako essentially covers all of the global anatomic pathology markets. www.Dako.com
Dako's Reagent Partnership Division provides clinical diagnostic products within specific proteins for turbidimetry and reagents for flow cytometry covering retail sales through distributors and OEM through partnerships.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE:TMO ) is the world leader in serving science, enabling our customers to make the world healthier, cleaner and safer. With annual revenues of $10.5 billion, we have approximately 34,000 employees and serve over 350,000 customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental and industrial process control settings. Serving customers through two premier brands, Thermo Scientific and Fisher Scientific, we help solve analytical challenges from routine testing to complex research and detection. The Thermo Scientific brand represents a complete range of high-end analytical instruments as well as laboratory equipment, software, services, consumables and reagents to enable integrated laboratory workflow solutions. Fisher Scientific provides a complete portfolio of laboratory equipment, chemicals, supplies and services used in healthcare, scientific research, safety and education. Together, we offer the most convenient purchasing options for customers, and continuously advance our technologies to accelerate the pace of scientific discovery, enhance value for customers, and fuel growth for shareholders and employees alike. Visit www.thermofisher.com.
Source: Dako
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
